David Lebowitz
Stock Analyst at Citigroup
(4.47)
Main Sectors:
25 Stocks
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
IONS Ionis Pharmaceutical... | Maintains: Strong Buy | 69 84 | 69.15 | 21.48% | 14 | Sep 3, 2025 | |
CYTK Cytokinetics | Maintains: Strong Buy | 77 84 | 56.97 | 47.45% | 4 | Sep 2, 2025 | |
CLDX Celldex Therapeutics | Maintains: Buy | 56 48 | 26.41 | 81.75% | 2 | Aug 20, 2025 | |
SDGR Schrodinger | Downgrades: Neutral | 35 20 | 20.59 | -2.87% | 10 | Aug 15, 2025 | |
ASND Ascendis Pharma | Maintains: Strong Buy | 243 290 | 204.05 | 42.12% | 14 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 88 103 | 86.85 | 18.6% | 6 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 31 38 | 29.72 | 27.86% | 2 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 15 22 | 15.76 | 39.59% | 4 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 58 67 | 52.86 | 26.75% | 5 | Jul 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | 83 129 | n/a | n/a | 6 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 45 56 | 40.09 | 39.69% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 14 10 | 19.96 | -49.9% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 4 2 | 1.52 | -1.32% | 6 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Sell | 32 45 | 65.37 | -31.16% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 65 68 | 72.95 | -6.79% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 382 | 443.01 | -13.77% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 103 96 | 55.43 | 73.19% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 18 12 | 6.05 | 98.35% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 170 164 | 456.35 | -64.06% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 36 39 | 19.92 | 95.78% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 20 21 | 15.6 | 34.62% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 435 405 | 6.38 | 6247.96% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 13 14 | 1.55 | 803.23% | 2 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 324 300 | n/a | n/a | 2 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 10 5 | n/a | n/a | 2 | Aug 10, 2021 |